Frank Bepperling

1.2k total citations
24 papers, 824 citations indexed

About

Frank Bepperling is a scholar working on Critical Care and Intensive Care Medicine, Cardiology and Cardiovascular Medicine and Biochemistry. According to data from OpenAlex, Frank Bepperling has authored 24 papers receiving a total of 824 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Critical Care and Intensive Care Medicine, 7 papers in Cardiology and Cardiovascular Medicine and 6 papers in Biochemistry. Recurrent topics in Frank Bepperling's work include Trauma, Hemostasis, Coagulopathy, Resuscitation (16 papers), Blood transfusion and management (6 papers) and Chronic Kidney Disease and Diabetes (4 papers). Frank Bepperling is often cited by papers focused on Trauma, Hemostasis, Coagulopathy, Resuscitation (16 papers), Blood transfusion and management (6 papers) and Chronic Kidney Disease and Diabetes (4 papers). Frank Bepperling collaborates with scholars based in Germany, France and United States. Frank Bepperling's co-authors include Cornelius Jungheinrich, Manfred Wargenau, J. Waitzinger, Norbert Vogt, W Sauermann, Willem van Oeveren, R Huet, Jean‐François Baron, J. F. Baron and Christian Mélot and has published in prestigious journals such as Anesthesiology, Anesthesia & Analgesia and Critical Care.

In The Last Decade

Frank Bepperling

24 papers receiving 786 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Frank Bepperling Germany 12 586 290 222 187 164 24 824
Franco Turani Italy 13 158 0.3× 201 0.7× 206 0.9× 192 1.0× 160 1.0× 34 867
Stein Tølløfsrud Norway 14 184 0.3× 201 0.7× 182 0.8× 132 0.7× 35 0.2× 23 513
Nick J. Koning Netherlands 14 171 0.3× 312 1.1× 223 1.0× 113 0.6× 79 0.5× 23 596
Rosemarie Maddi United States 15 362 0.6× 696 2.4× 421 1.9× 111 0.6× 38 0.2× 29 1.3k
Fellery de Lange Netherlands 16 142 0.2× 280 1.0× 275 1.2× 62 0.3× 66 0.4× 33 603
G. Wietasch Netherlands 16 95 0.2× 492 1.7× 224 1.0× 59 0.3× 63 0.4× 50 829
Fritz Daudel Germany 13 141 0.2× 247 0.9× 104 0.5× 80 0.4× 62 0.4× 27 535
Mariam Noorani Tanzania 11 166 0.3× 186 0.6× 145 0.7× 79 0.4× 12 0.1× 19 565
Alexandra Gendo Austria 11 147 0.3× 172 0.6× 41 0.2× 195 1.0× 123 0.8× 18 737
Alain Roman Belgium 12 74 0.1× 221 0.8× 61 0.3× 64 0.3× 84 0.5× 29 626

Countries citing papers authored by Frank Bepperling

Since Specialization
Citations

This map shows the geographic impact of Frank Bepperling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Bepperling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Bepperling more than expected).

Fields of papers citing papers by Frank Bepperling

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Bepperling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Bepperling. The network helps show where Frank Bepperling may publish in the future.

Co-authorship network of co-authors of Frank Bepperling

This figure shows the co-authorship network connecting the top 25 collaborators of Frank Bepperling. A scholar is included among the top collaborators of Frank Bepperling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frank Bepperling. Frank Bepperling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Morioka, Nobutada, Makoto Ozaki, Michiaki Yamakage, et al.. (2013). The Volume Effect and Safety of 6% Hydroxyethyl Starch 130/0.4 in Patients Undergoing Major Elective Surgery: An Uncontrolled, Open-Labeled, Multi-Center Study. Open Journal of Anesthesiology. 3(7). 326–337. 2 indexed citations
2.
Yamakage, Michiaki, Frank Bepperling, Manfred Wargenau, & Hideki Miyao. (2012). Pharmacokinetics and safety of 6 % hydroxyethyl starch 130/0.4 in healthy male volunteers of Japanese ethnicity after single infusion of 500 ml solution. Journal of Anesthesia. 26(6). 851–857. 8 indexed citations
3.
Ertmer, Christian, Hans Christian Wulf, Hugo Van Aken, et al.. (2012). Efficacy and safety of 10% HES 130/0.4 versus 10% HES 200/0.5 for plasma volume expansion in cardiac surgery patients.. PubMed. 103(2). 111–22. 6 indexed citations
4.
Ertmer, Christian, Hugo Van Aken, Hinnerk Wulf, et al.. (2011). Efficacy and safety of 10% HES 130/0.4 versus 10% HES 200/0.5 for plasma volume expansion in cardiac surgery patients. Critical Care. 15(S1). 5 indexed citations
5.
Klemm, Eckart, et al.. (2007). Hemodilution Therapy With Hydroxyethyl Starch Solution (130/0.4) in Unilateral Idiopathic Sudden Sensorineural Hearing Loss. Otology & Neurotology. 28(2). 157–170. 31 indexed citations
6.
Gandhi, Sweeta D., Richard B. Weiskopf, Cornelius Jungheinrich, et al.. (2007). Volume Replacement Therapy during Major Orthopedic Surgery Using Voluven® (Hydroxyethyl Starch 130/0.4) or Hetastarch. Anesthesiology. 106(6). 1120–1127. 66 indexed citations
7.
Jungheinrich, Cornelius, W Sauermann, Frank Bepperling, & Norbert Vogt. (2004). Volume Efficacy and Reduced Influence on Measures of Coagulation Using Hydroxyethyl Starch 130/0.4 (6%) with an Optimised in???Vivo???Molecular Weight in Orthopaedic Surgery. Drugs in R&D. 5(1). 1–9. 82 indexed citations
8.
Waitzinger, J., et al.. (2003). Hydroxyethyl Starch (HES) [130/0.4],??? a New HES Specification. Drugs in R&D. 4(3). 149–157. 55 indexed citations
9.
10.
Woessner, Ralph, Markus T. Grauer, H.‐J. Dieterich, et al.. (2003). Influence of a Long-Term, High-Dose Volume Therapy with 6% Hydroxyethyl Starch 130/0.4 or Crystalloid Solution on Hemodynamics, Rheology and Hemostasis in Patients with Acute Ischemic Stroke. Pathophysiology of Haemostasis and Thrombosis. 33(3). 121–126. 26 indexed citations
11.
12.
Jungheinrich, Cornelius, et al.. (2002). The Pharmacokinetics and Tolerability of an Intravenous Infusion of the New Hydroxyethyl Starch 130/0.4 (6%, 500 mL) in Mild-to-Severe Renal Impairment. Anesthesia & Analgesia. 95(3). 544–551. 101 indexed citations
13.
Jungheinrich, Cornelius, et al.. (2002). Pharmacokinetics of the Generic Formulation Propofol 1% Fresenius in Comparison with the Original Formulation (Disoprivan?? 1%). Clinical Drug Investigation. 22(7). 417–427. 5 indexed citations
14.
15.
Huet, R, et al.. (2000). A novel hydroxyethyl starch (Voluven®) for effective perioperative plasma volume substitution in cardiac surgery. Canadian Journal of Anesthesia/Journal canadien d anesthésie. 47(12). 1207–1215. 126 indexed citations
16.
Mols, Pierre, et al.. (1999). Etude de la faisabilite et des effets hemodynamiques de la perfusion d'un volume limite de NaCl a 7.2 %/hydroxyethyl amidon 6% 200/0,5 au cours de la reanimation prehospitaliere et du transport aux urgences de traumatises. Journal Européen des Urgences. 12(3). 99–104. 3 indexed citations
17.
Bepperling, Frank, et al.. (1999). HES 130/0.4, a new HES specification: tissue storage after multiple infusions in rats. Critical Care. 3(Suppl 1). P153–P153. 8 indexed citations
18.
Bepperling, Frank, et al.. (1999). HES 130/0.4, a new HES specification: pharmacokinetics after multiple infusions of 10% solutions in healthy volunteers. Critical Care. 3(Suppl 1). P154–P154. 7 indexed citations
19.
20.
Golf, S. W., Frank Bepperling, & V. Graef. (1984). Effect of 5α-dihydrocorticoids on enzymes of gluconeogenesis in rat liver. Steroids. 43(1). 85–91. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Franco Turani Breakdown of academic impact, for papers by Stein Tølløfsrud Breakdown of academic impact, for papers by Nick J. Koning Breakdown of academic impact, for papers by Rosemarie Maddi Breakdown of academic impact, for papers by Fellery de Lange Breakdown of academic impact, for papers by G. Wietasch Breakdown of academic impact, for papers by Fritz Daudel Breakdown of academic impact, for papers by Mariam Noorani Breakdown of academic impact, for papers by Alexandra Gendo Breakdown of academic impact, for papers by Alain Roman
Rankless by CCL
2026